894801-96-8Relevant academic research and scientific papers
Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists
Takahashi, Toshiyuki,Haga, Yuji,Sakamoto, Toshihiro,Moriya, Minoru,Okamoto, Osamu,Nonoshita, Katsumasa,Shibata, Takunobu,Suga, Takuya,Takahashi, Hirobumi,Hirohashi, Tomoko,Sakuraba, Aya,Gomori, Akira,Iwaasa, Hisashi,Ohe, Tomoyuki,Ishihara, Akane,Ishii, Yasuyuki,Kanatani, Akio,Fukami, Takehiro
scheme or table, p. 3511 - 3516 (2010/08/06)
Continuing medicinal chemistry studies to identify spiropiperidine-derived NPY Y5 receptor antagonists are described. Aryl urea derivatives of a variety of spiropiperidines were tested for their NPY Y5 receptor binding affinities. Of the spiropiperidines
HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS
-
Page/Page column 205, (2008/06/13)
Compounds of formula (I) Q-L-W-C(=X)-Z-P wherein Q is an amine of the formula-N (R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6-or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N-CN or S; Z is NR 3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.
